Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q504Y2
UPID:
PKDCC_HUMAN
Alternative names:
Protein kinase domain-containing protein, cytoplasmic; Protein kinase-like protein SgK493; Sugen kinase 493; Vertebrate lonesome kinase
Alternative UPACC:
Q504Y2; D6W5A0; Q96I09
Background:
Extracellular tyrosine-protein kinase PKDCC, also known as Sugen kinase 493, plays a pivotal role in organogenesis through the phosphorylation of extracellular and endogenous proteins in the secretory pathway. It is essential for longitudinal bone growth, mediating chondrocyte differentiation and possibly involved in protein transport from the Golgi to the plasma membrane.
Therapeutic significance:
Linked to Rhizomelic limb shortening with dysmorphic features, PKDCC's understanding could pave the way for innovative treatments targeting skeletal dysplasia, offering hope for affected individuals.